Senti Biosciences, Inc. SNTI
0.33
(0.01)
(2.94%)
as of 25 Sep
- Market cap
- $10.0M
- P/E
- 0.0×
Follow SNTI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (466.46%) | (255.03%) | (393.35%) | (394.62%) |
+8 more TTM periods Free account |
|
| (97.52%) | (85.19%) | (82.43%) | (86.19%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(571.34%) | (408.39%) | (276.92%) | (191.69%) | |
Average Days of Receivables |
1,376.28 | 108.35 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.22) | (1.19) | (1.94) | (1.91) | |
Free Cash Flow |
(37.94) | (36.94) | (43.64) | (50.21) | |
Capital Expenditures |
0.11 | (0.07) | (0.19) | (0.13) | |
Piotroski F-Score |
3.00 | 3.00 | — | — | |
| Other line items | |||||
Cash ROIC |
(1,242.68%) | (320.65%) | (197.39%) | (245.89%) | |
Accounts Receivable Turnover |
0.30 | 1.73 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,394.80% | 1,303.30% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,930.43% | 980.99% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
408.18% | 225.73% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.77 | 0.72 | 0.71 | 1.05 | |
Depreciation/Fixed assets |
0.28 | 0.28 | 0.28 | 0.20 | |
Capex/Depreciation |
0.04 | (0.02) | (0.05) | (0.04) | |
Revenue per Share |
0.04 | 0.08 | 0.00 | 0.00 | |
Operating CF per Share |
(1.22) | (1.19) | (1.93) | (1.91) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
(0.09) | 0.03 | 0.00 | 0.00 | |
Net Profit Margin |
(3,789.30%) | (2,000.27%) | 0.00% | 0.00% |
Columns are period end dates